Australia markets close in 5 hours 38 minutes

GSK Jan 2025 25.000 put

OPR - OPR Delayed price. Currency in USD
Add to watchlist
0.15000.0000 (0.00%)
As of 11:34AM EDT. Market open.
Full screen
Previous close0.1500
Open0.1500
Bid0.0000
Ask0.0000
Strike25.00
Expiry date2025-01-17
Day's range0.1500 - 0.1500
Contract rangeN/A
Volume7
Open interest988
  • Reuters

    GSK whistleblower claims drugmaker cheated US government over Zantac cancer risk

    (Reuters) -GSK has been sued by an independent Connecticut laboratory that accused the drugmaker of defrauding the U.S. government and taxpayers by concealing cancer risks in Zantac, once a blockbuster heartburn drug. In a whistleblower complaint filed on Monday, Valisure said GSK violated the federal False Claims Act by hiding the risks for nearly four decades while Medicare, Medicaid and other health programs covered billions of dollars of prescriptions. The New Haven-based lab said its testing in 2019 revealed that Zantac, also known as ranitidine, could form a cancer-causing carcinogen known as NMDA and was therefore "unfit for human consumption."

  • Evening Standard

    FTSE 100 Live 17 May: LandSec shares fall on results, GSK in £1.25bn final Haleon stake sale

    GSK and Land Securities are in the FTSE 100 spotlight after the drugs giant sold its final Haleon shares and the property firm posted results. The sale of GSK’s remaining 4% stake raised £1.25 billion, having held 13% following its 2022 demerger of the Panadol and Sensodyne business. Land Securities revealed a smaller full-year loss of £341 million amid “robust” rental growth across its estate.

  • Yahoo Finance UK

    Trending tickers: Tesla, Reddit, Walmart and GSK

    The latest investor updates on stocks that are trending on Friday.